July 26, 2014 7:57 AM ET


Company Overview of Coherus Biosciences Inc

Company Overview

Coherus Biosciences Inc., a biopharmaceutical company, engages in the development, manufacture, and commercialization of biologic therapeutics. The company develops biologic medicines primarily for the treatment of oncology and inflammatory diseases. It serves customers globally. The company has a strategic collaboration with Daiichi Sankyo. Coherus Biosciences Inc. was founded in 2010 and is based in Redwood City, California.

201 Redwood Shores Parkway

Suite 200

Redwood City, CA 94065

United States

Founded in 2010



Key Executives for Coherus Biosciences Inc

Age: 59
Chief Financial Officer
Chief Business Officer
Age: 54
Senior Vice President of Inflammatory Diseases
Age: 67
Senior Vice President of Oncology
Compensation as of Fiscal Year 2014.

Coherus Biosciences Inc Key Developments

Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 in Chronic Plaque Psoriasis (RaPsOdy)

Coherus BioSciences Inc. announced the start of its Phase 3 trial of CHS-0214, a proposed biosimilar of etanercept (Enbrel(R)), in chronic plaque psoriasis (the RaPsOdy trial). This announcement follows the recent initiation of a Phase 3 trial of CHS-0214 in rheumatoid arthritis. The Phase 3 psoriasis trial is a 48-week, randomized, double-blind, active-control, parallel-group, multicenter, global study in subjects with active, chronic plaque psoriasis who are naïve to systemic biologic therapy. The study will seek to demonstrate biosimilarity between CHS-0214 and Enbrel(R) in terms of efficacy, safety and immunogenicity. The primary efficacy endpoint is based on percent improvement in the Psoriasis Area and Severity Index (PASI) at 12 weeks.

Coherus BioSciences, Inc. Appoints V. Bryan Lawlis to Board of Directors

Coherus BioSciences Inc. announced the appointment of V. Bryan Lawlis to its Board of Directors.

Coherus Biosciences Inc Announces Initiation of Phase 3 Trial of CHS-0214 (Investigational Etanercept Biosimilar) in Rheumatoid Arthritis

Coherus Biosciences Inc. announced the start of its Phase 3 trial of CHS-0214, an investigational etanercept biosimilar, in rheumatoid arthritis (RA). The Phase 3 trial is a randomized, double-blind, active-control, parallel-group, multicenter, global study in subjects with active RA who have demonstrated an inadequate response to methotrexate. The primary endpoint is ACR 20 at 24 weeks. The initiation of a CHS-0214 Phase 3 study is an important event for RA patients. This trial of biosimilar etanercept advances its goal to expand access to this life-changing medication for patients with RA. This trial marks transition to a Phase 3 company. Coherus brings complementary capabilities with the potential to support accelerated entry into the biosimilar market for Baxter.

Similar Private Companies By Industry

Company Name Region
Melanx Corporation United States
LeadScope, Inc. United States
X-Ceptor Therapeutics, Inc. United States
CytoSolv Inc. United States
CMD Bioscience LLC United States

Recent Private Companies Transactions

Private Placement
May 9, 2014
February 24, 2014
InteKrin Therapeutics, Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Coherus Biosciences Inc, please visit www.coherus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.